544312 HAMPS

Hamps Bio Share Price

 

 

Start SIP in HAMPS

Start SIP

Performance

  • Low
  • ₹18
  • High
  • ₹19
  • 52 Week Low
  • ₹17
  • 52 Week High
  • ₹35
  • Open Price₹18
  • Previous Close₹17
  • Volume8,000
  • 50 DMA₹21.75
  • 100 DMA₹23.61
  • 200 DMA-

Investment Returns

  • Over 1 Month -5.36%
  • Over 3 Month -19.1%
  • Over 6 Month -36.84%
  • Over 1 Year -40.24%

Smart Investing Starts Here Start SIP with Hamps Bio for Steady Growth!

Invest Now

Hamps Bio Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 54.3
  • PEG Ratio
  • -
  • Market Cap Cr
  • 16
  • P/B Ratio
  • 1.9
  • Average True Range
  • 1.08
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.15
  • RSI
  • 41.7
  • MFI
  • 65.2

Hamps Bio Financials

Hamps Bio Technicals

EMA & SMA

Current Price
₹18.55
+ 1.67 (9.89%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 2
  • 20 Day
  • ₹19.93
  • 50 Day
  • ₹21.75
  • 100 Day
  • ₹23.61
  • 200 Day
  • -

Resistance and Support

18.51 Pivot Speed
  • R3 18.64
  • R2 18.60
  • R1 18.55
  • S1 18.46
  • S2 18.42
  • S3 18.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Hamps Bio Ltd. specializes in Pharmaceutical Formulation and Freeze-Dried Ingredients with two core divisions. Operating across Gujarat, Maharashtra, Rajasthan, and Madhya Pradesh, it serves B2B and B2C markets with therapeutic medicines and innovative freeze-dried food products.

Hamps Bio Ltd has an operating revenue of Rs. 17.14 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 6% is okay, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 23%, which signals a healthy balance sheet. From an O'Neil Methodology perspective, the stock has an EPS Rank of 5 which is a POOR score indicating inconsistency in earnings, a RS Rating of 23 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 156 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Hamps Bio Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Half Yearly Results (Revised) issue of equity shares in the ratio of 1:1 of Rs. 10/-.
2025-07-29 Bonus issue
2025-05-28 Audited Results
Date Purpose Remarks
2025-09-09 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 10/-.

Hamps Bio F&O

Hamps Bio Shareholding Pattern

71.99%
0%
24.06%
3.95%

About Hamps Bio

  • NSE Symbol
  • HAMPS
  • BSE Symbol
  • 544312
  • Chairman & Managing Director
  • Mr. Herrik Mountbaton Shah
  • ISIN
  • INE0QBD01018

Similar Stocks to Hamps Bio

Hamps Bio FAQs

Hamps Bio share price is ₹18 As on 26 January, 2026 | 00:29

The Market Cap of Hamps Bio is ₹16.2 Cr As on 26 January, 2026 | 00:29

The P/E ratio of Hamps Bio is 54.3 As on 26 January, 2026 | 00:29

The PB ratio of Hamps Bio is 1.9 As on 26 January, 2026 | 00:29

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23